Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America

Clinical Infectious Diseases

Volumn 49, Issue 5, 2009, Pages 651-681

  Aberg, Judith A ^a   Kaplan, Jonathan E ^b   Libman, Howard ^c   Emmanuel, Patricia ^e   Anderson, Jean R ^f   Stone, Valerie E ^d   Oleske, James M ^g   Currier, Judith S ^h   Gallant, Joel E ^f  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Medicine and Dentistry   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HLA B ANTIGEN; RNA; TESTOSTERONE;

AGE DISTRIBUTION; BEHAVIORAL MEDICINE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BREAST CANCER; CANCER SCREENING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMORBIDITY; CONDYLOMA ACUMINATUM; CONTRACEPTION; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; FAMILY HEALTH; HEALTH CARE PERSONNEL; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LABORATORY TEST; MATERNAL CARE; MEDICAL SOCIETY; MENOPAUSE; METABOLIC DISORDER; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREGNANCY TEST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROLOGY; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; SURVIVAL RATE; SYPHILIS; TESTOSTERONE BLOOD LEVEL; THORAX RADIOGRAPHY; TOXOPLASMA GONDII; TUBERCULOSIS; UTERINE CERVIX CANCER; VACCINATION; VERTICAL TRANSMISSION; VIRUS HEPATITIS;

AIDS SERODIAGNOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CHRONIC DISEASE; COMORBIDITY; HIV INFECTIONS; HUMANS; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 70149095523     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605292     Document Type: Review

References (96)

1. Aberg JA, Gallant JE, Anderson J, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39:609-629
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-I-infected adults and adolescents. Department of Health and Human Services, 2008. Available at: http://www.aidsinfb.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 6 February 2009.
3. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use ofantiretroviral agents in pediatric HIV infection, 2008. Available at: http://www.aidsinfo nih.gov. Accessed 6 February 2009.
4. US Public Health Service. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 transmission in the United States. 2008. Available at: http://www.aidsinfb.nih.gov/ Guidelines/GuidelineDetail.aspx?MenuItem = Guidelines&Search = Off &GuidelineID=9&ClassID = 2. Accessed 6 February 2009.
5. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-1585
6. American Diabetes Association. Clinical practice recommendations 2008. Diabetes Care 2008; 31:S 1-108.
7. European Association for the Study of the L (EASL). EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
8. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410
9. Soriano V, Puoti M., Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-1089
10. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-88 (Pubitemid 351228130)
11. Branson BM., Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55(RR-14):1-17.
12. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627
13. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-15):1-48.
14. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule: United States, 2009. MMWRMorb Mortal Wky Rep 2009;57(53):Q1-4.
15. New York State Department of Health AIDS Institute. Mental health care for people with HIV infection: clinical guidelines for the primary care practitioner. Available at: http://www.hivguidelines.org/Content .aspx?PageID = 261. Accessed 6 February 2009.
16. Schambelan M., Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-I infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 200231:257-275 (Pubitemid 35278626)
17. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50(RR-11): 1-52.
18. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal WkIy Rep 2009;58(RR-4):1-207.
19. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. 2008. Available at: http://www.aidsinfo.nih .gov/Guidelines/GuidelineDetail. aspx?MenuItem = Guidelines8t Search = Off&GuidelineID = 2118tClassID = 4. Accessed 6 February 2009.
20. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Larry K, Pickering M, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
21. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resis- tance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128
22. Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. Recomm Rep 2003;52(RR-12):1-24.
23. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55(RR-11):1-94.
24. Centers for Disease Control and Prevention-Division of HIV/AIDS Prevention. Cases of HIV infection and AIDS in the United States and dependent areas, 2006. HIV/AIDS Surveillance Report, V. 18, March 2008. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/ reports/2006report/ default.htm. Accessed 6 February 2009.
25. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072-1078
26. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180
27. ACOG committee opinion scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000 (replaces number 219, August 1999). Int J Gynaecol Obstet 2001; 73:279-281
28. Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006;55:592-597
29. Field MJ, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990:52-77.
30. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:1193-1254
31. Centers for Disease Control and Prevention (CDC). False-positive oral fluid rapid HIV tests-New York City, 2005-2008. MMWR Morb Mortal Wkly Rep 2008;57:660-665
32. Centers for Disease Control and Prevention. Notice to readers: protocols for confirmation of reactive rapid HIV tests. MMWR Morb Mortal Wkly Rep 2004;53:221-222
33. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 2008;122:1127-1134
34. Read JS. Diagnosis of HIV-I infection in children younger than 18 months in the United States. Pediatrics 2007; 120:e1.547-62.
35. Soriano V, Geretti AM, Perno CF, et al. Optimal use of maraviroc in clinical practice. AIDS 2008;22:2231-2240
36. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:499-505.
37. Tungsiripat M, Drechsler H, Sarlone C, Amyot K, Laffey E, Aberg J. Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic. J Int Assoc Physicians AIDS Care (Chic 111) 2008; 7:88-90.
38. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
39. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52(RR-11):1-77.
40. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 1997; 46(RR-15): 1-10.
41. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005 191:1435-1441 (Pubitemid 40563354)
42. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 2003;32:727-734
43. Roback JD. CMV and blood transfusions. Rev Med Virol 2002; 12: 211-219
44. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006 194:247-255 (Pubitemid 44087197)
45. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40.
46. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-2129 (Pubitemid 34437347)
47. National Center for Infectious Diseases Division of HIV/AIDS. 1993 Revised classification system for hiv infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
48. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994;43(RR-12):1-10.
49. Minkoff HL, Eisenberger-Matityahu D, Feldman J, Burk R, Clarke L. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol 1999;180:824-836 (Pubitemid 29200548)
50. Paramsothy P, Duerr A, Heilig CM., et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 200435:484-491 (Pubitemid 38420657)
51. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119
52. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005;293:1471-1476
53. ACOG Committee Opinion. Routine cancer screening. Vol.247. Washington, DC: American Cancer Society, 2000.
54. Pantanowitz L, Connolly JL. Pathology of the breast associated with HIV/AIDS. Breast J 2002;8:234-243
55. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest 2002;20:452-457 (Pubitemid 34686340)
56. ACOG practice bulletin. Breast cancer screening. Number 42, April 2003. Int J Gynaecol Obstet 2003;81:313-323
57. Qaseem A, Snow V, Sherif K, Aronson M., Weiss KB, Owens DK. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007 146:511-515 (Pubitemid 351650560)
58. Havens PL, Mofenson LM. Evaluation and management of the infant exposed to HIV-I in the United States. Pediatrics 2009;123:175-187
59. Green H, Gibb DM, Compagnucci A, et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial. Antivir Ther 2006; 11:857-867 (Pubitemid 44736177)
60. Violari A, Cotton MF, Gibb DM., et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244
61. Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007;120:e236-43.
62. McConnell MS, Byers RH, Frederick T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 2005;38:488-494
63. Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot R. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence. Pediatr Infect Dis J 2006;25:987-994 (Pubitemid 44657806)
64. Wiener L, Mellins CA, Marhetka S, Battles HB. Disclosure of an HIV diagnosis to children: history, current research, and future directions. J Dev Behav Pediatr 2007;28:155-166 (Pubitemid 46624845)
65. American Academy of Pediatrics (AAP). Disclosure of illness status to children and adolescents with HIV infection. American Academy of Pediatrics Committee on Pediatrics AIDS. Pediatrics 1999; 103:164-166
66. Nozyce ML, Lee SS, Wiznia A, et al. A. behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006;117:763-770 (Pubitemid 46063218)
67. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007;97:1047-1052 (Pubitemid 351181927)
68. A consensus statement on health care transitions for young adults with special health care needs. Pediatrics 2002 110:1304-1306 (Pubitemid 35425171)
69. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 356:1723-1735 (Pubitemid 46658704)
70. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296
71. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383 (Pubitemid 41800673)
72. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331.el-7. (Pubitemid 46497918)
73. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 200519:1051-1058 (Pubitemid 40961145)
74. Van Der Valk M., Friis-Moller N, Sabin C, et al. Effect of interventions to improve dyslipidaemia [abstract PL12.2]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection (Glasgow, UK). 2006.
75. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999 13:2188-2189 (Pubitemid 29509609)
76. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-797
77. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473-2482 (Pubitemid 350145179)
78. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev 2007 2:CD005645. (Pubitemid 351805807)
79. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87
80. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999 13:F35-43. (Pubitemid 29286695)
81. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-234
82. Bangsberg DR, Hecht FM., Charlebois ED, et al. Adherence to protease inhibitors, HIV-I viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366
83. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000133:21-30. (Pubitemid 30432540)
84. Bakken S, Holzerner WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen, in persons with HIV/AIDS. AIDS Patient Care STDS 2000 14:189-197 (Pubitemid 30225313)
85. Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 200744:1493-1499 (Pubitemid 46801595)
86. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physicianpatient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 200419:1096-1103 (Pubitemid 39552579)
87. Malcolm SE, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 2003; 1.5: 251-261
88. Dugdale DC, Epstein R, Pantilat SZ. Time and the patient-physician relationship. J Gen Intern Med 1999; 14(Suppl l):S34-40.
89. Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009;48:248-256
90. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005;19:423-431 (Pubitemid 40446189)
91. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001286:2857-2864 (Pubitemid 33126929)
92. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:384-390
93. Flanigan TP, Mitty JA. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult. Clin Infect Dis 2006;42:1636-1638
94. Stone VE. Optimizing the care of minority patients with HIV/AIDS. Clin Infect Dis 200438:400-404 (Pubitemid 38200118)
95. Washington DL, Bowles J, Saha S, et al. Transforming clinical practice to eliminate racial-ethnic disparities in healthcare. J Gen Intern Med 2008;23:685-691
96. Willard S, Angelino AF. The need for sociocultural awareness to maximize treatment acceptance and adherence in individuals initiating HIV therapy. J Int. Assoc Physicians AIDS Care 2008;7:S17-21.